STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0)July to SeptemberNet sales amounted to MSEK 0 (0)Net…
New offering provides an all-in-one AI platform optimized for mammography, that seamlessly integrates artificial intelligence (AI) applications from iCAD to…
SAN MATEO, Calif.--(BUSINESS WIRE)--Model N, Inc. (NYSE: MODN), the leader in revenue optimization and compliance today announced that Model N…
The ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or…
ZURICH, SWITZERLAND / ACCESSWIRE / November 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss…
Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerabilityCompany expects to engage FDA…
TORONTO, ON / ACCESSWIRE / November 27, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…
Clearmind Medicine CEO, Dr. Adi Zuloff-Shani, and MAPS founder and psychedelic sector pioneer, Rick Doblin, will discuss the growing and…
MitoCareX Bio has met its second milestone as part of its joint venture agreement with the Company TEL AVIV, Israel,…
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end…